Dry Age-Related Macular Degeneration

Primary Investigator: Andre Witkin, MD

Title: A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration

Sponsor: University of Virginia

Brief Summary
This is a phase II study to assess the safety and effectiveness of oral doxycycline (ORACEA®), compared to placebo, to determine if it can slow the progression of geographic atrophy in patients who have dry age-related macular degeneration (AMD).

Inclusion Criteria
Clinical diagnosis of geographic atrophy secondary to dry age-related macular degeneration in at least one eye

Study Length and Visits: 6 study visits over a 25-month period with additional testing

Age Range: 55-85 years

Gender: Both

Payment: None

Contact: Carly Satsuma, 617-636-5489